About this episode
Prof Fred Saad (University of Montreal) drops in to chat about the interesting condition that is non-metastatic castration-resistant prostate cancer (nmCRPC). Which men are at risk of developing metastases? When should we use an AR pathway inhibitor? Why PSMA PET/CT should NOT be used. And hear his thoughts on "dabbling" in prostate cancer!
Also joined by Professor Shankar Siva and Dr Louise Kostos from Peter MacCallum Cancer Centre. Hosted as ever by Dr Renu Eapen and Professor Declan Murphy.
Fred was on a speaker tour in Australia supported by Bayer Pharmaceuticals and this Themed Podcast is supported by Bayer, Silver Partners of GU Cast.
Update - we mentioned that darolutamide was the only ARPI listed for reimbursement in Australia (true at time of recording). We can update that all TGA approved ARPIs for nmCRPC are now reimbursed in Australia.
Even better on our YouTube channel
Get every episode summarized
Each time GU Cast | Urology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from GU Cast | Urology Podcast
Is Copper the new Gold??! Co-PSMA trial in European Urology
GU Cast | Urology Podcast
EAU Prostate Cancer Guideline Update
GU Cast | Urology Podcast
Journal club #7 | proPSMA and Penile Fractures(!)
GU Cast | Urology Podcast
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
GU Cast | Urology Podcast